[Federal Register: June 23, 2009 (Volume 74, Number 119)]
[Notices]               
[Page 29720]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23jn09-85]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 22, 2009, Noramco Inc., 
Division of Ortho-McNeil, Inc., 500 Swedes Landing Road, Wilmington, 
Delaware 19801, made application by letter to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of 
Tapentadol (9780), a basic class of controlled substance listed in 
schedule II.
    The company plans to bulk manufacture the above listed controlled 
substance for distribution to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such a substance, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, VA 22152; and must be filed no later 
than August 24, 2009.

    Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-14695 Filed 6-22-09; 8:45 am]

BILLING CODE 4410-09-P